Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
Aug 1, 2026, 07:51

Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?

Christopher Kirkham, Group Leader in Ex Vivo Biology at IQVIA Laboratories, shared a post on LinkedIn:

“Could platelet activation become a liability for your antibody programme?

Platelet safety is often overlooked until a signal emerges during development. However, unintended interactions with platelets can have significant consequences, including platelet depletion, activation and thrombotic complications.

Early assessment of platelet binding, activation and function can help identify potential liabilities before they become costly development challenges.

At IQVIA Laboratories, we combine flow cytometry and aggregometry to provide a comprehensive ex vivo assessment of antibody-mediated platelet responses, supporting more informed candidate selection and risk assessment earlier in development.”

Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?

Stay updated with Hemostasis Today.